ClinicalTrials.gg
RecruitingNCT06125925Updated Dec 11, 2023

Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)

An interventional study of Radiofrequency catheter ablation (RFCA) and Medical Therapy in Atrial Fibrillation and HFpEF - Heart Failure With Preserved Ejection Fraction, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-12-11.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
436
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Atrial Fibrillation by The First Affiliated Hospital with Nanjing Medical University — 3 open to participants now, 3 under way, none of them phase 3. Atrial Fibrillation · The First Affiliated Hospital with Nanjing Medical University.

Planned enrollment
3rd of 14
436 · median 205
Started
2023
the only one that year
No phase
12 of 16
3 open now
Registered
14th of 16
by date

Among the 16 studies in Atrial Fibrillation by The First Affiliated Hospital with Nanjing Medical University, this one is the 3rd largest by planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 12 with no phase, and was the 14th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

3 of the 16 studies in Atrial Fibrillation by The First Affiliated Hospital with Nanjing Medical University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Atrial Fibrillation by The First Affiliated Hospital with Nanjing Medical University, or all of them as a file.
02

Study summary

To investigate whether RFCA is superior to AADs in AF patients with HFpEF on the basis of optimized anti-heart-failure drug therapy regarding their longterm clinical outcomes.

Read the detailed description

Background: Atrial Fibrillation (AF) is a common cardiac rhythm disorder and radiofrequency catheter ablation (RFCA) has become the first-line therapy in the symptomatic AF patients. Heart failure is often the sister disease with AF. Recently, RFCA was found to be superior to antiarrhythmic drugs (AADs) in heart failure patients with AF and reduced ejection fraction (HFrEF), regarding all-cause mortality and hospitalization for worsening heart failure (HF). However, in heart failure patients with AF and preserved ejection fraction (HFpEF), it remains unknown whether RFCA is superior to AADs in an even larger population, despite several nonrandomized retrospective studies. Thus, this prospective, multi-center, randomized controlled trial aims to investigate whether RFCA could better improve the clinical outcome of AF patients with HFpEF than longterm AADs use.

Aim of this study: To investigate whether RFCA is superior to AADs in AF patients with HFpEF on the basis of optimized anti-heart-failure drug therapy regarding their longterm clinical outcomes.

Design: The STABLE-SR-IV trial is an international, prospective, multi-center, randomized controlled trial. In this trial, physical examination, echocardiogram, NT-proBNP and other blood test would be assessed before enrollment. Those who conform to all the inclusion criteria and absent from any exclusion criteria would enter into a run-in period of 5 weeks (±7 days). Anticoagulation and anti-heart-failure therapy for HFpEF must be optimized according to the current guideline. After the run-in period, inclusion and exclusion criteria would be reassessed. Thereafter, all the subjects enrolled would be randomized into RFCA arm and Medical Therapy arm with a 1:1 manner, namely 218 subjects in each arm. Each arm will follow the protocol of RFCA and medical therapy, respectively. Follow-up duration of this study is up to 2\~3 years (12 month enrollment).

03

Conditions studied

  • Atrial Fibrillation
  • HFpEF - Heart Failure With Preserved Ejection Fraction

Browse trials for

Keywords

  • atrial fibrillation
  • HFpEF
  • radiofrequency catheter ablation
  • drug therapy
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Symptomatic paroxysmal or persistent atrial fibrillation
  • CHADS2-VASc score≥ 2
  • Conform to the diagnosis of HFpEF

    1. II-IV level;
    2. (LVEF)≥ 50%;
    3. NT-proBNP≥ 300 pg/mL under sinus rhythm or NT-proBNP≥ 600 pg/mL under atrial fibrillation or flutter;
    4. Evidence of left ventricular diastolic dysfunction/raised left ventricular filling pressure on echocardiogram.
  • Sign

Exclusion criteria

Exclusion Criteria:

  • A below 2 years due to any non-cardiovascular condition
  • Reversible atrial fibrillation, such as hyperthyroidism or hypokalemia-related atrial fibrillation
  • Prior atrial fibrillation ablation
  • Left atrial size≥ 55 mm
  • Heart failure due to any of the following: known genetic hypertrophic cardiomyopathy, infiltrative cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, constrictive pericarditis, active myocarditis, cardiac tamponade, or uncorrected primary valvular disease
  • Previous cardiac transplantation, complex congenital heart disease, rheumatic heart disease
  • Any for radiofrequency catheter ablation, antiarrhythmic drugs or anticoagulation
  • Acute coronary syndrome, cardiac surgery, angioplasty or cerebrovascular accident within 12 weeks before enrollment
  • Severe hepatic and renal dysfunction
  • > 50 kg/m2
  • Female in period of pregnancy or breast-feeding
  • Any conditions that, in the opinion of the investigator, may render the patient unable to complete the study
  • Involved in other studies

The inclusion and exclusion criteria would be reassessed after run-in period and the cut-off of NT-proBNP would be set as >125 pg/ml under sinus rhythm or >365 pg/ml under AF/atrial flutter (AFL).

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
436 participants (estimated)

Study arms

  • Experimental
    Radiofrequency catheter ablation (RFCA)

    Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.

    Procedure: Radiofrequency catheter ablation (RFCA)

  • Active comparator
    Medical therapy

    AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.

    Drug: Medical Therapy

Interventions

  • ProcedureRadiofrequency catheter ablation (RFCA)

    Radiofrequency ablation is adopted in the study, instead of cryo ablation, surgical ablation or pulsed field ablation. 3-dimensional model is constructed after transseptal puncture. Circumferential pulmonary vein isolation (CPVI) is performed with irrigated contact force catheter. Previously published STABLE-SR approach is recommended as the ablation strategy beyond CPVI.

  • DrugMedical Therapy

    AADs should be prescribed according to the current guidelines, such as amiodarone, dronedarone, or propafenone. In brief, rhythm control is preferred, including electric cardioversion. However, rate control should be considered if rhythm control is contraindicated, intolerated or unpreferred by patients.

06

What researchers measure

Primary outcomes

  1. Composite endpoint of worsening heart failure requiring unplanned hospitalizations or urgent visits, and cardiovascular death (Time-to-first event analysis)

    Time frame: From randomization until completion of the planned follow-up, up to 36 months

Secondary outcomes

  1. Time to hospitalization or urgent visits for heart failure

    Worsening heart failure includes worsening heart failure requiring unplanned hospitalization and worsening heart failure requiring urgent visits.

    Time frame: From randomization until completion of the planned follow-up, up to 36 months

  2. Time to hospitalization for heart failure

    In addition to signs and symptoms of HF, the patient should also receive treatment specifically directed at HF, including at least 1 of the following: 1) significant augmentation in oral diuretic therapy; 2) initiation of intravenous diuretic (even a single dose) or vasoactive agent (eg, vasodilator, vasopressor, or inotropic therapy); or 3) mechanical circulatory support or fluid removal. Unplanned hospitalization is defined as any unscheduled hospital admission with a length of stay that either exceeds 24 h or crosses a calendar day, and not planned by the investigators. In case the hospitalization is classified as planned by the Investigator and the time interval between the decision to admit and the admission is less than 24 hours, the End Point and Adverse Event Committee will give final classification concerning planned or unplanned.

    Time frame: From randomization until completion of the planned follow-up, up to 36 months

  3. Time to urgent visits for heart failure

    Worsening of Heart Failure Requiring Unplanned Urgent Visits Patients have an urgent, unscheduled office or emergency visit for HF with signs, symptoms, and diagnostic testing results identical to those already described for an HF hospitalization. The patient must also (with the exception of significant augmentation in oral diuretic therapy) require therapy similar to that previously described for an HF hospitalization.

    Time frame: From randomization until completion of the planned follow-up, up to 36 months

  4. Time to cardiovascular death

    All deaths due to cardiovascular reasons and all heart transplants because of terminal HF. Deaths due to worsening of HF, acute coronary syndrome, cerebrovascular accident.

    Time frame: From randomization until completion of the planned follow-up, up to 36 months

  5. Time to all-cause death

    All deaths were reviewed and adjudicated by the Clinical Events Committee

    Time frame: From randomization until completion of the planned follow-up, up to 36 months

  6. Time to cardiovascular hospitalization

    Unplanned Hospitalization due to Cardiovascular Reasons Any in-hospital stay over one date change due to cardiovascular reason, which includes worsening of HF, acute coronary syndrome, cerebrovascular accidents, or other cardiovascular events, and not planned by the investigator. In case the hospitalization is classified as planned by the investigator, and the time interval between the decision to hospitalize and the hospitalization is less than 24 hours, the End Point and Adverse Event Committee will give final classification concerning planned or unplanned.

    Time frame: From randomization until completion of the planned follow-up, up to 36 months

  7. Total number of worsening heart failure events and cardiovascular deaths

    Time frame: From randomization until completion of the planned follow-up, up to 36 months

  8. Change in quality of life - KCCQ score

    KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ Total Symptom Score incorporates the symptom domains into a single score. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.

    Time frame: Baseline, 3 months, 12 months

  9. Change in quality of life - MLWHFQ

    The Mayo AF-Specific Symptom Inventory (MAFSI) is a questionnaire comprised of a 10-item AF symptom checklist that asked about both the frequency and severity of each symptom. MAFSI frequency of symptoms over the past month was recorded as 0 (never), 1 (rarely), 2 (sometimes), 3 (often), and 4 (always) for each of the 10 items listed in the questionnaire. The 10 item responses were summed for a total Frequency Score that ranged from 0 (no AF symptoms) to 40 (worst score).

    Time frame: Baseline, 3 months, 12 months

  10. Change in 6-minute walk test from baseline to Month 3 and Month 12

    The 6-minute walk test is a sub-maximal exercise test used to assess aerobic capacity and endurance.

    Time frame: Baseline, 3months, 12 months

  11. Change in H2FPEF score from baseline to Month 3 and Month 12

    The H2FPEF score is a clinical scoring system used to assess the likelihood of heart failure with preserved ejection fraction (HFpEF) in patients with suspected heart failure. It helps in differentiating HFpEF from other causes of dyspnea. The total score ranges from 0 to 5, with higher scores indicating a greater likelihood of HFpEF.

    Time frame: Baseline, 3 months, 12 months

  12. Change in N-terminal pro-B type natriuretic peptide (NT-proBNP) from baseline to Month 3 and Month 12

    Elevated levels of NT-pro BNP are indicative of increased cardiac stress and can help in the diagnosis, assessment, and monitoring of heart failure.

    Time frame: Baseline, 3 months, 12 months

  13. Change in NYHA class from baseline to Month 3, 6 and 12

    NYHA class is a widely used system for assessing the functional status and severity of heart failure symptoms in patients, with NYHA class IV being the worst.

    Time frame: Baseline, 3 months, 12 months

  14. Time to change of diuretics

    Based on status of baseline diuretics, the intention to treat population will be divided into patients with baseline diuretics and patients without. For patients without the usage of baseline diuretics, the outcome of changes in diuretics is the initiation of diuretics during the follow-up period. For patients without the usage of baseline diuretics, the outcomes including: 1. permanent discontinuation; 2. escalation defined as increased dosage, iv fused diuretic or combination with another diuretic; 3. de-escalation (including permanent discontinuation or decrease in dosage); Changes in diuretic therapy are analyzed in a time-to-first event fashion using a multivariable Cox regression model to obtain hazard ratios (HRs) and 95% confidence intervals (CIs).

    Time frame: From randomization until completion of the planned follow-up, up to 36 months

  15. Change in atrial fibrillation burden

    Atrial fibrillation burden refers to the amount of time that a person with atrial fibrillation spends in an irregular heart rhythm over a specific period, using a Holter monitor.

    Time frame: Baseline, 12 months

  16. Time to Atrial Fibrillation recurrence (RFCA arm)

    A 30-second episode of AF in ablation group following the 90 day blanking period, confirmed through blinded review by an ECG Core Lab Committee was used for defining the endpoint of recurrent AF.

    Time frame: From randomization until completion of the planned follow-up, up to 36 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2026, 36 months after the start.

Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 36 months is close to that.

Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2023
First posted
Nov 9, 2023
StartActual
Nov 6, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Dec 11, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 11, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06125925
Responsible party
Minglong Chen (Director of Heart Center, The First Affiliated Hospital with Nanjing Medical University) — Principal investigator
First posted
Nov 9, 2023
Start date
Nov 6, 2023
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Dec 11, 2023

Study contacts

Hailei Liu, PhD
Contact
liuhailei@njmu.edu.cn
+86-18094226858
Nan Wu, MD
Contact
wunannjmu@163.com
+86-18351977986

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion